GenVec genvec.com


Public list: BIO 2016 (619) Pharma Startups (4732)

GenVec (NASDAQ: GNVC) is a clinical-stage biopharmaceutical company and pioneer in the development of AdenoVerse gene delivery technology platform.

GenVec (NASDAQ: GNVC) is a clinical-stage biopharmaceutical company and pioneer in the development of AdenoVerse gene delivery technology platform.

Company (Acquired)

Phone: 240-632-0740

Fax:

910 Clopper Road
Suite 220N
Gaithersburg, 20878
Maryland, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
GenVec $103M Jun 16, 2017
See all 13 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related GenVec Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors

Competitors

Company Status Description Investors

Pharmasset

Princeton, New Jersey, United States
AcquiredPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset's research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. In January 2012, Pharm...Show allLogin to see details

Enzo Biochem

New York, New York, United States
IPO / Went publicEnzo Biochem is a life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and aims to provide reference laboratory services to the medical community. Founded in 1976, the company have concentrated on the development of enabling technologies in the areas of gene regulation and gene modification. Many of the company's technologies are applicable to the biomedical and pharmaceutical research markets, and the company are...Show allLogin to see details
See all 13 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Adenoviral vector encoding human atonal homolog-1 (hath1) Oct 09, 2015 Apr 24, 2018 Patent
Malaria antigens and methods of use Nov 12, 2013 Dec 05, 2017 Patent
Modified serotype 28 adenoviral vectors May 28, 2013 Oct 17, 2017 Patent
Affenadenovirus (gorilla) or adenoviral vectors and methods of use Jan 11, 2016 Aug 08, 2017 Patent
Herpes simplex virus vaccine May 16, 2013 Jun 13, 2017 Patent
See all 24 patents